Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Treatment of ADHD

MARLBOROUGH, Mass.--(BUSINESS WIRE) November 10, 2017 --Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for dasotraline, a novel...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news